Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
CEL-SCI Corp
CVMCurrent price
0.26 USD
-0.012 USD (-4.24%)
Last closed
0.29 USD
Company
cel-sci.com
ISIN
US1508376076
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
Capitalization
44 709 628 USD
Yield for 12 month
-84.05 %
1Y
3Y
5Y
10Y
15Y
CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. Address: 8229 Boone Boulevard, Vienna, VA, United States, 22182
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
7.73 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-3 958 334 USD
Last Year
-3 883 386 USD
Current Quarter
-983 208 USD
Last Quarter
-988 762 USD
Key Figures CVM
1 year
3 years
5 years
10 years
EBITDA
-25 523 336 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-61.41 %
PEG Ratio
–
Return On Equity TTM
-250.20 %
Wall Street Target Price
7.73 USD
Revenue TTM
28 558 USD
Book Value
0.16 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-62.70 %
Dividend Yield
–
Gross Profit TTM
-25 355 346 USD
Earnings per share
-0.52 USD
Diluted Eps TTM
-0.52 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CVM
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History CVM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
28.08.1996
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
0
Consistent Years
0
Continuous Dividends
1
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:25
Payout Ratio
–
Last Split Date
15.06.2017
Stock Valuation CVM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
11 797.42
Enterprise Value EBITDA
-3.71
Price Book MRQ
5.20
Financials CVM
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CVM
For 52 weeks
0.49 USD
3.23 USD
50 Day MA
0.99 USD
Shares Short Prior Month
4 278 104
200 Day MA
1.43 USD
Short Ratio
18.05
Shares Short
4 427 317
Short Percent
7.13 %
BeatStart